Lindis Biotech GmbH
LINDIS Biotech Announces Formation of Advisory Board to Support Next Phase of Growth
DGAP-News: Lindis Biotech GmbH
/ Key word(s): Personnel
LINDIS Biotech Announces Formation of Advisory Board to Support Next Phase of Growth Martinsried, Germany, December 21, 2021 – LINDIS Biotech GmbH, a biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline with three clinical product candidates in immuno-oncology, today announced the formation of its Advisory Board comprising three industry experts in the fields of business development, clinical development, and regulatory affairs. The new committee will be a valuable resource to shape and guide the strategy of LINDIS Biotech as the company continues to advance its pre-clinical and clinical candidates. “The formation of our Advisory Board with leading experts in their respective field is an important step to further drive the company’s development with compelling long-term as well as near-term inflection points ahead,” said Dr. Horst Lindhofer, founder and CEO of LINDIS Biotech. “The diverse areas of expertise and insight of the Advisory Board will be essential in the execution of our strategy. It will help us accelerate the development of our drug candidates, steer future applications and forge new commercial partnerships. I am very much looking forward to working with this renowned group, as we further explore the potential of our unique combination of highly effective tumor cell destruction and patient-specific vaccination.” Inaugural members of the LINDIS Biotech Advisory Board include: Prof. Dr. med. Markus M. Heiss – Prof. Heiss is Director of the Clinic for Visceral, Tumor, Transplantation and Vascular Surgery at the Cologne-Merheim Hospital. He holds the Chair of Surgery 1 at the University of Witten/Herdecke and was President of the Association of Lower Rhine-Westphalian Surgeons (NRW Surgeons) in 2016-2017. His scientific focus, among others, includes the clinical development of trifunctional bispecific antibodies in gastrointestinal tumors and he has served as a consultant and coordinating investigator for Germany in the clinical development of catumaxomab i.e. in Malignant Ascites. More Information: About CATUMAXOMAB Catumaxomab is a bispecific trifunctional antibody that binds directly to the tumor cell with one of its binding sites and activates two essential components of the immune system with the other binding sites: T cells and Fc-gamma receptor positive cells (macrophages etc.). The antibody recognizes and binds to all EpCAM-positive tumor cells, including critical cancer stem cells and all CD3-positive T cells. The EpCAM marker is present on almost all carcinomas and, therefore, is a promising approach for targeted cancer treatment. In 2009, catumaxomab was approved in Europe for the indication of malignant ascites (the buildup of fluid containing cancer cells in the space around the organs in the abdomen) and has proven its safety and anti-tumor efficacy in the clinic. About LINDIS Biotech GmbH LINDIS Biotech GmbH, a biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline with three clinical product candidates in immuno-oncology, was founded in 2010 by Dr. Horst Lindhofer, inventor of the Triomab(R) platform. LINDIS Biotech is the only company that owns a technology which combines extremely effective tumor cell destruction with a patient-specific vaccination based on trifunctional bispecific antibodies. The Company is therefore ideally positioned in the area of cancer immunotherapeutic agents. As the first product to emerge from this platform and a breakthrough in the development of bispecific antibodies, catumaxomab was approved in 2009 in Europe under the name Removab(R) for the indication of malignant ascites and has proven its safety and anti-tumor efficacy in the clinic. For more information please contact: LINDIS Biotech GmbH MEDIA INQUIRIES MC Services AG
21.12.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Lindis Biotech GmbH |
Am Klopferspitz 19 | |
82152 Martinsried | |
Germany | |
Phone: | +4989200066440 |
E-mail: | info@lindisbiotech.de |
Internet: | https://www.lindisbiotech.com/ |
EQS News ID: | 1260178 |
End of News | DGAP News Service |